Finvest
SLNO Biotechnology · Rare disease · Acquired · Single product · Thesis updated July 2, 2026

Soleno became a completed deal

01 Running thesis

The stock story ended

Soleno is no longer a normal public equity story. On April 5, 2026, it signed a merger agreement to be bought by Neurocrine Biosciences for $53.00 per share in cash. That changed the key question from “How fast can VYKAT XR grow?” to “Will the deal close?”

That question has now been answered. Neurocrine completed the acquisition on May 18, 2026. The tender offer accepted about 46.4 million shares, or about 88.9% of Soleno’s outstanding common stock, and the remaining shares were converted into the same $53.00 per share cash price.

For a reader looking back, the bull case was simple: the tender offer closed on time and holders received cash. The bear case, deal failure or a long delay, did not happen. Any future upside or downside from VYKAT XR now belongs to Neurocrine, not standalone SLNO shareholders.

May 2026▲Neurocrine completed the Soleno acquisition for $53.00 per share in cash. The merger arbitrage case closed successfully.
May 2026→Soleno’s Q1 filing showed the thesis had shifted to deal completion risk after the Neurocrine merger agreement and tender offer.
Apr 2026▼Soleno withdrew its European Marketing Authorization Application for VYKAT XR. That removed a major piece of the old standalone expansion case.
Feb 2026▲The 2025 results confirmed a strong VYKAT XR launch, with $190.4 million of net product revenue and $20.1 million of net income.
Nov 2025▲Q3 2025 revenue rose to $66.0 million and Soleno posted its first profitable quarter. Patient discontinuation became a metric to watch.
Aug 2025▲Q2 2025 gave the first hard evidence of VYKAT XR demand, with $32.7 million of net product revenue in the first full quarter of sales.
02 Business model

One drug, then a sale

Soleno was a rare disease biotech built around one approved product, VYKAT XR, also called diazoxide choline. The drug treats hyperphagia, or extreme hunger, in people with Prader-Willi syndrome.

The company began booking VYKAT XR sales in the second quarter of 2025. For the year ended December 31, 2025, it reported $190.4 million of net product revenue and $20.1 million of net income. That was its first profitable year.

By 2026, the business model was dominated by the Neurocrine deal. Cash from the buyer, not future prescription growth, became the main source of value for public holders.

03 Product portfolio

What Neurocrine bought

Cash cow

VYKAT XR

VYKAT XR was Soleno’s only FDA-approved product. It treats hyperphagia in Prader-Willi syndrome and drove all disclosed product revenue in 2025.

Growth engine

U.S. VYKAT XR launch

The U.S. launch began in the second quarter of 2025. Revenue rose from $32.7 million in Q2 2025 to $66.0 million in Q3 2025 and $91.7 million in Q4 2025.

Option

European VYKAT filing

Soleno withdrew its European Marketing Authorization Application in April 2026. That removed a major piece of the former standalone expansion plan.

Option

Neurocrine integration

VYKAT XR is now part of Neurocrine after the May 2026 merger close. Future strategy, spending, and expansion decisions sit with the buyer.

04 Business segments

No real segment mix

VYKAT XR net product revenue100%growing fast
Other disclosed revenue segments0%flat

Soleno reported one operating focus: rare disease therapeutics led by VYKAT XR. For 2025, disclosed net product revenue was $190.4 million, and no separate revenue segment mix was provided.

05 Risk factors

What could have gone wrong

Deal failure risk

High impact · Low odds

Before May 18, 2026, the main risk was that Neurocrine’s tender offer failed or did not meet closing conditions. That would likely have pushed the stock back toward a standalone drug-launch valuation. The deal has since closed, so this risk is now mainly historical.

We watchMerger completion filings and tender offer results.

Deal delay risk

Medium impact · Low odds

A delay past the expected end of Q2 2026 close would have created uncertainty and opportunity cost. Holders would have waited longer for the $53.00 per share cash payment. This did not become the final outcome.

We watchTender offer expiration dates, extensions, and closing announcements.

European expansion loss

Medium impact · High odds

Soleno withdrew its European application for VYKAT XR in April 2026. That delayed any European revenue stream and removed a key part of the old standalone thesis. Neurocrine could revisit Europe later, but Soleno public holders no longer own that option.

We watchAny new Neurocrine filing or regulatory update for VYKAT XR in Europe.

Single-product dependence

Medium impact · Medium odds

Soleno depended on one approved drug. Before the sale, weak patient retention, payer pushback, or safety issues with VYKAT XR would have hit almost the whole business. After the acquisition, this risk moved to Neurocrine’s portfolio.

We watchVYKAT XR prescription trends, patient discontinuation rates, and payer coverage.
06 Quick answers

In one breath

Is Soleno Therapeutics still publicly traded?

No. Neurocrine completed the acquisition of Soleno on May 18, 2026. Soleno shares were converted into the right to receive $53.00 per share in cash.

What was Soleno’s main product?

Soleno’s main product was VYKAT XR, a diazoxide choline extended-release medicine. It was approved for hyperphagia, or extreme hunger, in Prader-Willi syndrome.

Why did the Soleno thesis change so much?

The company first looked like a rare disease launch story after VYKAT XR started selling well. The Neurocrine merger changed the stock into a merger arbitrage story, where deal closing mattered more than long-term sales growth.

What happened to Soleno’s European plan?

Soleno voluntarily withdrew its European Marketing Authorization Application in April 2026. That delayed European commercialization and weakened the old standalone growth plan.